Medicis/Ucyclyd Pharma
Executive Summary
Medicis acquires privately held Ucyclyd for $23.4 mil. in cash. Payments include $15 mil. after the April 19 acquisition; $5.7 mil. on the first anniversary of the deal, subject to the continuation of a supply agreement for the material for Ucyclyd's lead product Buphenyl; and $2.7 mil. upon regulatory approval of an I.V. version of sodium benzoate/sodium phenylacetate, now available in oral solution. Buphenyl, an orphan drug approved for the treatment of urea cycle disorders, has historically had approximately $6 mil. in annual sales
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth